These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 18445011)

  • 41. Haemostatic efficacy and safety of bolus and continuous infusion of recombinant factor VIIa are comparable in haemophilia patients with inhibitors undergoing major surgery. Results from an open-label, randomized, multicenter trial.
    Pruthi RK; Mathew P; Valentino LA; Sumner MJ; Seremetis S; Hoots WK;
    Thromb Haemost; 2007 Oct; 98(4):726-32. PubMed ID: 17938794
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Whole blood coagulation in children with thrombocytopenia and the response to platelet replacement, recombinant factor VIIa, and a potent factor VIIa analogue.
    Larsen OH; Clausen N; Persson E; Ezban M; Ingerslev J; Sørensen B
    Br J Haematol; 2009 Jan; 144(1):99-106. PubMed ID: 19016728
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Experiences in the prevention of arthropathy in haemophila patients with inhibitors.
    Jimenez-Yuste V; Rodriguez-Merchan EC; Alvarez MT; Quintana M; Martin-Salces M; Hernandez-Navarro F
    Haemophilia; 2008 Nov; 14 Suppl 6():28-35. PubMed ID: 19134031
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacokinetics and pharmacodynamics of rFVIIa and new improved bypassing agents for the treatment of haemophilia.
    Agersø H; Tranholm M
    Haemophilia; 2012 Jul; 18 Suppl 5():6-10. PubMed ID: 22757678
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry.
    Parameswaran R; Shapiro AD; Gill JC; Kessler CM;
    Haemophilia; 2005 Mar; 11(2):100-6. PubMed ID: 15810910
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A direct thrombin inhibitor studied by dynamic whole blood clot formation. Haemostatic response to ex-vivo addition of recombinant factor VIIa or activated prothrombin complex concentrate.
    Sørensen B; Ingerslev J
    Thromb Haemost; 2006 Oct; 96(4):446-53. PubMed ID: 17003921
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Factor VIIa analog has marked effects on platelet function and clot kinetics in blood from patients with hemophilia A.
    Brophy DF; Martin EJ; Nolte ME; Kuhn JG; Barrett JC; Ezban M
    Blood Coagul Fibrinolysis; 2010 Sep; 21(6):539-46. PubMed ID: 20581663
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Single-dose (270 microg kg(-1)) recombinant activated factor VII for the treatment and prevention of bleeds in haemophilia A patients with inhibitors: experience from seven European haemophilia centres.
    Pan-Petesch B; Laguna P; Mital A; Stanley J; Torchet MF; Salek SZ; Salaj P
    Haemophilia; 2009 May; 15(3):760-5. PubMed ID: 19298382
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Thrombelastography-guided factor VIIa therapy in a surgical patient with severe hemophilia and factor VIII inhibitor.
    Pivalizza EG; Escobar MA
    Anesth Analg; 2008 Aug; 107(2):398-401. PubMed ID: 18633014
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Levels of prothrombin activation peptide F1+2 in patients with a bleeding tendency.
    Ingerslev J; Holm M; Christiansen K; Knudsen L; Négrier C
    Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S129-34. PubMed ID: 9819044
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evaluation of the overall haemostatic effect of recombinant factor VIIa by measuring thrombin generation and stability of fibrin clots.
    Dargaud Y; Prevost C; Lienhart A; Claude Bordet J; Negrier C
    Haemophilia; 2011 Nov; 17(6):957-61. PubMed ID: 21453422
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A Phase II clinical trial of a mixture of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors: haemostatic efficacy, safety and pharmacokinetics/pharmacodynamics.
    Shirahata A; Fukutake K; Takamatsu J; Shima M; Hanabusa H; Mugishima H; Amano K; Takedani H; Tamashima S; Matsushita T; Tawa A; Tanaka I; Higasa S; Kosaka Y; Fujii T; Sakai M; Migita M; Kawakami K; Ohashi Y; Saito H
    Haemophilia; 2013 Nov; 19(6):853-60. PubMed ID: 23738888
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Successful treatment of a patient with acquired haemophilia A with a combination of a low-dose rituximab and recombinant human FVIIa.
    Xu Y; Zhang X; Zhao Y; Zhao L; Qiu H; Wu D
    Haemophilia; 2013 Mar; 19(2):e95-6. PubMed ID: 23231056
    [No Abstract]   [Full Text] [Related]  

  • 54. Comparison of kaolin and tissue factor activated thromboelastography in haemophilia.
    Young G; Zhang R; Miller R; Yassin D; Nugent DJ
    Haemophilia; 2010 May; 16(3):518-24. PubMed ID: 20028419
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Recombinant factor VIIa: unregulated continuous use in patients with bleeding and coagulopathy does not alter mortality and outcome.
    Ganguly S; Spengel K; Tilzer LL; O'neal B; Simpson SQ
    Clin Lab Haematol; 2006 Oct; 28(5):309-12. PubMed ID: 16999720
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Patient- and caregiver-reported bleeding symptoms and reasons for starting and stopping treatment with recombinant factor VIIa: analysis of the Dosing Observational Study in Haemophilia (DOSE).
    Valentino LA; Walsh CE; Reding MT; Young GA; Levendoglu-Tugal O; Cooper DL
    Haemophilia; 2012 Jul; 18(4):554-60. PubMed ID: 22348407
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluation of thromboelastography for monitoring recombinant activated factor VII ex vivo in haemophilia A and B patients with inhibitors: a multicentre trial.
    Young G; Ebbesen LS; Viuff D; Di Paola J; Konkle BA; Negrier C; Pasi J; Ingerslev J
    Blood Coagul Fibrinolysis; 2008 Jun; 19(4):276-82. PubMed ID: 18469548
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Improved clot formation by combined administration of activated factor VII (NovoSeven) and fibrinogen (Haemocomplettan P).
    Tanaka KA; Taketomi T; Szlam F; Calatzis A; Levy JH
    Anesth Analg; 2008 Mar; 106(3):732-8, table of contents. PubMed ID: 18292410
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The effect of tissue factor concentration on calibrated automated thrombography in the presence of inhibitor bypass agents.
    van Veen JJ; Gatt A; Bowyer AE; Cooper PC; Kitchen S; Makris M
    Int J Lab Hematol; 2009 Apr; 31(2):189-98. PubMed ID: 18190585
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Management and monitoring of recombinant activated factor VII.
    Ingerslev J; Christiansen K; Calatzis A; Holm M; Sabroe Ebbesen L
    Blood Coagul Fibrinolysis; 2000 Apr; 11 Suppl 1():S25-30. PubMed ID: 10850560
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.